| Literature DB >> 19937005 |
J Tichelaar1, M C Richir, H J Avis, H J Scholten, N F Antonini, Th P G M De Vries.
Abstract
PURPOSE: Although the importance of rational prescribing is generally accepted, the teaching of pharmacotherapy to undergraduate medical students is still unsatisfactory. Because clinical teachers are an important role model for medical students, it is of interest to know whether this extends to therapeutic decision-making. The aim of this study was to find out which factors contribute to the drug choices made by medical students and their teachers (general practitioners and clinical specialists).Entities:
Mesh:
Year: 2009 PMID: 19937005 PMCID: PMC2840661 DOI: 10.1007/s00228-009-0743-3
Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN: 0031-6970 Impact factor: 2.953
Summary of the written patient cases presented to the participants for choosing a (drug) treatment
| Patient case | Uncomplicated (A) vs complicated (B) | Situated in general practice or the outpatient clinic |
|---|---|---|
| Bronchial asthma | A | Woman, age 22. History: - |
| Currently: Acute asthma attack a few hours ago, lasting about 5min. Works in pet shop. Working diagnosis: bronchial asthma | ||
| B | Woman, age 22. History: migraine for 6months. Takes acetaminophen 2 × 500mg and metoclopramide supp. 20mg during migraine attack. No attacks since using propranolol tab. 80mg daily | |
| Currently: Acute asthma attack a few hours ago, lasting about 5min. Works in pet shop. Working diagnosis: bronchial asthma | ||
| Osteoarthritis | A | Woman, age 63. History: - |
| Currently: increasing pain in right knee for a few weeks. Working diagnosis: osteoarthritis | ||
| B | Woman, age 61. History: osteoarthritis in right knee for 10years. Ibuprofen tab. 400mg when necessary for 1year; no pain | |
| Currently: stomach pain for 7days. Working diagnosis: NSAID-related gastric symptoms | ||
| Essential hypertension | A | Woman, age 52. History: - |
| Currently: high blood pressure detected during a sports physical examination. No complaints. Now: BP 160/105 mmHg. Working diagnosis: essential hypertension | ||
| B | Man, age 62. History: myocardial infarction in 1999. Since then: atenolol 50mg daily, acetosal 80mg daily. Six weeks ago: recurrent high blood pressure 170/105mmHg; diet and exercise advice | |
| Currently: control visit: BP 170/100mmHg. Working diagnosis: essential hypertension, after 6weeks of not responding to diet, exercise advice and atenolol |
The treatments prescribed (%) by students, general practitioners and specialists for the uncomplicated (A) and complicated (B) cases
| Final-year medical students ( | Percentage | General practitioners ( | Percentage | Clinical specialists ( | Percentage | |||
|---|---|---|---|---|---|---|---|---|
| Bronchial asthma | A | 1 | β2 agonist | 90 | β2 agonist | 94 | β2 agonist | 52 |
| 2 | β2 agonist + steroid | 5 | β2 agonist + steroid | 6 | β2 agonist + steroid | 44 | ||
| 3 | Other | 5 | Other | 4 | ||||
| B | 1 | β2 agonist | 40 | β2 agonist | 41 | β2 agonist + steroid | 40 | |
| 2 | Steroid | 25 | β2 agonist + steroid | 24 | β2 agonist | 20 | ||
| 3 | Β2 agonist + steroid | 20 | β2 agonist + steroid + stop beta antagonist | 24 | β2 agonist + stop beta antagonist | 8 | ||
| 4 | Other | 15 | Other | 11 | β2 agonist + steroid + stop beta antagonist | 8 | ||
| β2 agonist + steroid + prednisone | 8 | |||||||
| Other | 16 | |||||||
| Osteoarthritis | A | 1 | Prostaglandin inhibitor | 60 | Non-opioid analgesics | 53 | Prostaglandin inhibitor | 70 |
| 2 | Non-opioid analgesics | 25 | Prostaglandin inhibitor | 30 | Prostaglandin inhibitor + PPI | 13 | ||
| 3 | Prostaglandin inhibitor + PPI | 15 | Prostaglandin inhibitor + PPI | 17 | Non-opioid analgesics | 13 | ||
| Other | 4 | |||||||
| B | 1 | PPI | 40 | Non-opioid analgesics | 61 | PPI | 35 | |
| 2 | Prostaglandin inhibitor + PPI | 35 | Prostaglandin inhibitor + PPI | 17 | Non-opioid analgesics | 22 | ||
| 3 | Prostaglandin inhibitor | 10 | Prostaglandin inhibitor | 11 | Prostaglandin inhibitor + PPI | 17 | ||
| 4 | Opioid | 5 | PPI | 11 | Prostaglandin inhibitor | 13 | ||
| 5 | Other | 10 | Other | 13 | ||||
| Essential hypertension | A | 1 | Diuretics | 50 | Diuretics | 42 | Beta antagonist | 36 |
| 2 | Beta antagonist | 41 | Lifestyle advice | 27 | Diuretics | 28 | ||
| 3 | Lifestyle advice | 9 | Beta antagonist | 26 | Lifestyle advice | 24 | ||
| ACE inhibitor | 5 | ACE inhibitor | 8 | |||||
| Calcium antagonist | 4 | |||||||
| B | 1 | Diuretics | 46 | Beta antagonist | 48 | Beta antagonist | 44 | |
| 2 | ACE inhibitor | 23 | Diuretics | 26 | ACE inhibitor | 24 | ||
| 3 | Beta antagonist | 18 | ACE inhibitor | 21 | Diuretics | 12 | ||
| 4 | Lifestyle advice | 9 | Lifestyle advice | 5 | Beta antagonist + diuretics | 12 | ||
| 5 | Other | 4 | Other | 8 | ||||
PPI Proton pump inhibitor
Importance of factors affecting drug choice, as rated by students, general practitioners and clinical specialists
| Final-year medical students ( | General practitioners ( | Clinical specialists ( | ANOVA overall | |
|---|---|---|---|---|
| Practice-related factors | ||||
| Own clinical experience | 1.59 (1.40–1.79) | 2.32 (2.19–2.45)b | 2.06 (1.94–2.17)b | <0.001 |
| Easy administration of the drug(s) | 1.00 (0.83–1.17) | 1.08 (0.88–1.29) | 0.92 (0.77–1.07) | 0.34 |
| Patients’ convenience | 1.57 (1.39–1.76) | 1.90 (1.73–2.06)b | 1.83 (1.70–1.96)b | 0.013 |
| Compliance of the patient | 1.44 (1.28–1.60) | 1.79 (1.62–1.96)b | 1.78 (1.64–1.91)b | 0.002 |
| Drug-related factors | ||||
| Effectiveness of the drug(s) | 2.19 (2.07–2.31) | 2.28 (2.14–2.41) | 2.50 (2.40–2.60)b | <0.001 |
| Side effects of the drug(s) | 1.55 (1.38–1.73) | 2.19 (2.01–2.37)b | 2.00 (1.86–2.13)b | <0.001 |
| Costs of the drug(s) | 0.88 (0.72–1.04) | 1.40 (1.21–1.59)b | 0.96 (0.83–1.09) | <0.001 |
| Therapeutic spectrum of the drug(s) | 1.05 (0.89–1.21) | 1.64 (1.44–1.84)b | 1.67 (1.52–1.82)b | <0.001 |
| Information-related factors | ||||
| Standard treatment guidelines (STG) | 1.98 (1.82–2.14) | 2.17 (1.99–2.35) | 1.73 (1.58–1.87)b | <0.001 |
| Scientific literature | 1.23 (1.05–1.48) | 1.51 (1.31–1.71) | 2.10 (1.98–2.23)b | <0.001 |
| The opinion of colleagues | 1.18 (1.02–1.34) | 0.78 (0.60–0.95)b | 1.10 (0.97–1.24) | 0.001 |
| Information from the pharmaceutical industry | 0.60 (0.45–0.74) | 0.34 (0.23–0.46)b | 0.81 (0.69–0.93)b | <0.001 |
| Teaching-related factors | ||||
| Examples from clinical teachers | 2.06 (1.93–2.20)a | 0.60 (0.45–0.76) | 1.08 (0.93–1.23) | <0.001 |
| Education and postgraduate education | 1.30 (1.11–1.48) | 1.68 (1.50–1.86)b | 1.30 (1.15–1.44) | 0.003 |
Pooled data are presented as mean (95% CI). Differences among groups were analysed by means of the least-squared difference test: a P < 0.05 students vs. general practitioners and clinical specialists, b P < 0.05 vs. students
Factors with a score of score ≥2 on a scale of 0–3 were considered to have contributed to a considerable extent to the drug choice